MindMed Announces New Employee Inducement Grants
MindMed Appoints Matt Wiley as Chief Commercial Officer
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its price target lowered by analysts at Robert W. Baird from $27.00 to $16.00. They now have an "outperform" rating on the stock.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates